Ownership history in RHUMBLINE ADVISERS Β· 14 quarters on record
This page tracks every 13F SEC filing in which RHUMBLINE ADVISERS reported a position in INNATE PHARMA SA-SPONS ADR (IPHA). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π RHUMBLINE ADVISERS underperformed the S&P 500 by β36.6% annually on this IPHA position. Timing score: 33% (1/3 decisions correct). Average cost basis: $1.76. Maximum drawdown during holding period: β43.2%.
β Significantly underperformed the S&P 500 by 36.6% ann.
10 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
1 of 3 add/trim decisions correct
Best entry: $1.75 (2025 Q4) Β· Worst: $1.84 (2024 Q4)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
3 adds Β· 2 trims. Bought during 2 of 5 down-price quarters. π More buys than sells across the holding period.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.0% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size